These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7483646)

  • 1. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
    Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E
    Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dihydroergotamine as a nasal spray in the therapy of migraine attacks. Efficacy and tolerance].
    Jenzer G; Bremgartner MF
    Schweiz Rundsch Med Prax; 1990 Aug; 79(31-32):914-7. PubMed ID: 2203127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pharmacokinetics of dihydroergotamine administered by nasal spray.
    Humbert H; Cabiac MD; Dubray C; Lavène D
    Clin Pharmacol Ther; 1996 Sep; 60(3):265-75. PubMed ID: 8841149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydroergotamine nasal spray for the acute treatment of migraine.
    Ziegler D; Ford R; Kriegler J; Gallagher RM; Peroutka S; Hammerstad J; Saper J; Hoffert M; Vogel B; Holtz N
    Neurology; 1994 Mar; 44(3 Pt 1):447-53. PubMed ID: 8145914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
    Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
    Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
    Gawel M; Aschoff J; May A; Charlesworth BR;
    Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ergotamine, dihydroergotamine: current uses and problems.
    Tfelt-Hansen P
    Curr Med Res Opin; 2001; 17 Suppl 1():s30-4. PubMed ID: 12463275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
    Silvestro M; Orologio I; Tessitore A; Trojsi F; Tedeschi G; Russo A
    Expert Rev Neurother; 2024 Jun; 24(6):555-564. PubMed ID: 38655598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives.
    Young WB
    Headache; 1997; 37 Suppl 1():S42-5. PubMed ID: 9009473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.